Engineering Anti-Tumor T Cell Immunity

Engineering Anti-Tumor T Cell Immunity

T cell immunity is critical for protection against infectious agents as well as cancer. T cell immune response is a well orchestrated process that involves three key components. CD8+ T cells that harbor cytolytic machinery and can target and kill the tumor cells in an antigen specific manner, CD4+ T cells that can either “help” the generation of a productive CD8+ T cell or “regulate/suppress” i...

Talilmogene Iaherparepvec generates systemic T-cell-mediated anti-tumor immunity

Talimogene laherparepvec is an investigational oncolytic immunotherapy based on a modified herpes simplex virus type-1 (HSV-1) that is designed to selectively replicate in tumor tissue and to stimulate a systemic antitumor immune response. Intralesional administration of talimogene laherparepvec is intended to result in oncolysis within injected tumors. Iterative viral replication of virus with...

Engineering effective T-cell based antitumor immunity

The adoptive transfer of synthetic siRNA-mediated cblb-depleted autologous CD8+ T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augment the effectiveness of adoptively transferred immune cells.

CD47 in the tumor microenvironment limits cooperation between anti-tumor T cell immunity and radiation therapy

Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity

The tumor microenvironment (TME) fosters tumors by attenuating anti-tumor immunity, reinforcing tumor cell survival and increasing angiogenesis. Among the constituents of the TME, here, we focused on tumor-associated neutrophils (TANs). First, we found that the combination of poly I:C and inactivated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) synergistically suppre...